Leptomeningeal disease

Neurosurgery Clinics of North America

Volumn 22, Issue 1, 2011, Pages 67-78

  Groves, Morris D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; Leptomeningeal disease; Malignant meningitis; Neoplastic meningitis

Indexed keywords

AZACITIDINE; BEVACIZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; GANGLIOSIDE GD2 TARGETED MONOCLONAL ANTIBODY; GANGLIOSIDE GD2 TARGETED MONOCLONAL ANTIBODY I 131; GEFITINIB; HYDROXYUREA; IFOSFAMIDE; IODINE 131; MAFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; PEMETREXED; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; TEMOZOLOMIDE; THIOTEPA; TIAZOFURIN; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARACHNOIDITIS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER PATIENT; CENTRAL NERVOUS SYSTEM; CEREBELLUM INJURY; CEREBROSPINAL FLUID; CHILL; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE COURSE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PENETRATION; DRUG TARGETING; EARLY INTERVENTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; INCIDENCE; IRRITABILITY; MENINGEAL METASTASIS; MENINX; MENTAL DISEASE; MOLECULAR THERAPY; MUCOSA INFLAMMATION; NAUSEA; NECK PAIN; NEOPLASM; NEUROLOGIC DISEASE; NEUROPATHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SEIZURE; SIDE EFFECT; SPINAL CORD INJURY; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTINEOPLASTIC PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; MENINGEAL CARCINOMATOSIS; MENINGEAL NEOPLASMS; NEOPLASM METASTASIS;

EID: 78649404554     PISSN: 10423680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nec.2010.08.006     Document Type: Review

References (100)

1. DeAngelis L.M., Posner J.B. Neurologic complications of cancer. (Contemporary neurology series) 2009, Oxford University Press, New York.
2. Glass J.P., Melamed M.F., Chernik N.L., et al. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 1979, 29(10):1369-1375.
3. Altekruse S.F., Kosary C.L., Krapcho M., et al. SEER Cancer Statistics Review, 1975-2007 2010, National Cancer Institute, Bethesda (MD).
4. Groves M.D. The pathogenesis of neoplastic meningitis. Curr Oncol Rep 2003, 5(1):15-23.
5. Balm M., Hammack J. Leptomeningeal carcinomatosis. Presenting features and prognostic factors. Arch Neurol 1996, 53(7):626-632.
6. Gauthier H, Guilhaume MN, Bidard FC, et al, Survival of breast cancer patients with meningeal carcinomatosis. Ann Oncol, April 29, 2010. [Online].
7. Harstad L., Hess K.R., Groves M.D. Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neuro Oncol 2008, 10(6):1010-1018.
8. Wasserstrom W.R., Glass J.P., Posner J.B. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982, 49(4):759-772.
9. Suki D., Abouassi H., Patel A.J., et al. Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa. J Neurosurg 2008, 108(2):248-257.
10. Suki D., Hatiboglu M.A., Patel A.J., et al. Comparative risk of leptomeningeal dissemination of cancer after surgery or stereotactic radiosurgery for a single supratentorial solid tumor metastasis. Neurosurgery 2009, 64(4):664-674.
11. Chiang A.C., Massague J. Molecular basis of metastasis. N Engl J Med 2008, 359(26):2814-2823.
12. Groves M.D., Hess K.R., Puduvalli V.K., et al. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. J Neurooncol 2009, 92(2):229-234.
13. Herrlinger U., Wiendl H., Renninger M., et al. Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value. Br J Cancer 2004, 91(2):219-224.
14. Reijneveld J.C., Brandsma D., Boogerd W., et al. CSF levels of angiogenesis-related proteins in patients with leptomeningeal metastases. Neurology 2005, 65(7):1120-1122.
15. Stockhammer G.F., Poewe W.F., Burgstaller S.F., et al. Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology 2000, 54(8):1670-1676.
16. Chamberlain M.C., Sandy A.D., Press G.A. Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain. Neurology 1990, 40(3 Pt 1):435-438.
17. Freilich R.J., Krol G., DeAngelis L.M. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995, 38(1):51-57.
18. Clarke J.L., Perez H.R., Jacks L.M., et al. Leptomeningeal metastases in the MRI era. Neurology 2010, 74(18):1449-1454.
19. Glantz M.J., Hall W.A., Cole B.F., et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 1995, 75(12):2919-2931.
20. Chamberlain M.C., Kormanik P., Jaeckle K.A., et al. 111Indium-diethylenetriamine pentaacetic acid CSF flow studies predict distribution of intrathecally administered chemotherapy and outcome in patients with leptomeningeal metastases. Neurology 1999, 52(1):216-217.
21. Olson M.E., Chernik N.L., Posner J.B. Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. Arch Neurol 1974, 30(2):122-137.
22. Glantz M.J., Cole B.F., Glantz L.K., et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998, 82(4):733-739.
23. Gaynon P.S. Primary treatment of childhood acute lymphoblastic leukemia of non-T cell lineage (including infants). Hematol Oncol Clin North Am 1990, 4(5):915-936.
24. Walbert T., Groves M.D. Known and emerging biomarkers of leptomeningeal metastasis and its response to treatment. Future Oncol 2010, 6(2):287-297.
25. Corsini E., Bernardi G., Gaviani P., et al. Intrathecal synthesis of tumor markers is a highly sensitive test in the diagnosis of leptomeningeal metastasis from solid cancers. Clin Chem Lab Med 2009, 47(7):874-879.
26. van de Langerijt B., Gijtenbeek J.M., de Reus H.P., et al. CSF levels of growth factors and plasminogen activators in leptomeningeal metastases. Neurology 2006, 67(1):114-119.
27. Hegde U., Filie A., Little R.F., et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005, 105(2):496-502.
28. Chamberlain M.C., Kormanik P. Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch Neurol 1998, 55(4):506-512.
29. Chamberlain M.C., Kormanik P.R. Carcinomatous meningitis secondary to breast cancer: predictors of response to combined modality therapy. J Neurooncol 1997, 35(1):55-64.
30. Jaeckle K.A., Phuphanich S., Bent M.J., et al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer 2001, 84(2):157-163.
31. Grossman S.A., Spence A. NCCN clinical practice guidelines for carcinomatous/lymphomatous meningitis. Oncology 1999, 13(11A):144-152.
32. Chang E.L., Maor M.H. Standard and novel radiotherapeutic approaches to neoplastic meningitis. Curr Oncol Rep 2003, 5(1):24-28.
33. Feyer P., Sautter-Bihl M.L., Budach W., et al. DEGRO Practical Guidelines for palliative radiotherapy of breast cancer patients: brain metastases and leptomeningeal carcinomatosis. Strahlenther Onkol 2010, 186(2):63-69.
34. Chamberlain M.C. Neoplastic meningitis. Oncologist 2008, 13(9):967-977.
35. Cortes J., O'Brien S.M., Pierce S., et al. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 1995, 86(6):2091-2097.
36. Evans A.E., Gilbert E.S., Zandstra R. The increasing incidence of central nervous system leukemia in children. (Children's Cancer Study Group A). Cancer 1970, 26(2):404-409.
37. Smith M., Arthur D., Camitta B., et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996, 14(1):18-24.
38. Boogerd W., Dorresteijn L.D., van Der S., et al. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 2000, 55(1):117-119.
39. Boogerd W., Hart A.A., van der Sande J.J., et al. Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment. Cancer 1991, 67(6):1685-1695.
40. Boogerd W., van den Bent M.J., Koehler P.J., et al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur J Cancer 2004, 40(18):2726-2733.
41. de Wit M., Lange-Brock V., Kruell A., et al. Leptomeningeal metastases: results of different therapeutic approaches. J Clin Oncol 2007, 25(18).
42. Fizazi K., Asselain B., Vincent-Salomon A., et al. Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer 1996, 77(7):1315-1323.
43. Giglio P., Tremont-Lukats I.W., Groves M.D. Response of neoplastic meningitis from solid tumors to oral capecitabine. J Neurooncol 2003, 65(2):167-172.
44. Grant R., Naylor B., Greenberg H.S., et al. Clinical outcome in aggressively treated meningeal carcinomatosis. Arch Neurol 1994, 51(5):457-461.
45. Herrlinger U., Forschler H., Kuker W., et al. Leptomeningeal metastasis: survival and prognostic factors in 155 patients. J Neurol Sci 2004, 223(2):167-178.
46. Mencel P.J., DeAngelis L.M., Motzer R.J. Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma. Cancer 1994, 73(7):1892-1894.
47. Ozdogan M., Samur M., Bozcuk H.S., et al. Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection. Jpn J Clin Oncol 2003, 33(5):229-231.
48. Rudnicka H., Niwinska A., Murawska M. Breast cancer leptomeningeal metastasis-the role of multimodality treatment. J Neurooncol 2007, 84(1):57-62.
49. Siegal T., Lossos A., Pfeffer M.R. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 1994, 44(8):1463-1469.
50. Jabbour E., O'Brien S., Kantarjian H., et al. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood 2007, 109(8):3214-3218.
51. Bokstein F., Lossos A., Siegal T. Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer 1998, 82(9):1756-1763.
52. Glantz M.J., Cole B.F., Recht L., et al. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary?. J Clin Oncol 1998, 16(4):1561-1567.
53. Glantz M.J., Van H.A., Fisher R., et al. Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer 2010, 116(8):1947-1952.
54. Bleyer W.A., Poplack D.G. Intraventricular versus intralumbar methotrexate for central-nervous-system leukemia: prolonged remission with the Ommaya reservoir. Med Pediatr Oncol 1979, 6(3):207-213.
55. Chamberlain M.C., Kormanik P.A., Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 1997, 87(5):694-699.
56. Chamberlain M.C. Neoplastic meningitis. Neurologist 2006, 12(4):179-187.
57. Glantz M.J., Jaeckle K.A., Chamberlain M.C., et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999, 5(11):3394-3402.
58. Hitchins R.N., Bell D.R., Woods R.L., et al. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J Clin Oncol 1987, 5(10):1655-1662.
59. Shapiro W.R., Schmid M., Glantz M., et al. A randomized phase III/IV study to determine benefit and safety of cytarabine liposome injection for treatment of neoplastic meningitis. Proceedings of the American Society of Clinical Oncology 2006, 24(18).
60. Trump D.L., Grossman S.A., Thompson G., et al. Treatment of neoplastic meningitis with intraventricular thiotepa and methotrexate. Cancer Treat Rep 1982, 66(7):1549-1551.
61. Glantz M.J., LaFollette S., Jaeckle K.A., et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999, 17(10):3110-3116.
62. Bleyer W.A., Drake J.C., Chabner B.A. Neurotoxicity and elevated cerebrospinal-fluid methotrexate concentration in meningeal leukemia. N Engl J Med 1973, 289(15):770-773.
63. Grossman S.A., Finkelstein D.M., Ruckdeschel J.C., et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J Clin Oncol 1993, 11(3):561-569.
64. Bleyer W.A. Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat Rep 1981, 65(Suppl 1):89-98.
65. Groves M.D. Leptomeningeal carcinomatosis: diagnosis and management. Intracranial metastases: current management strategies 2004, 309-330. Blackwell Futura, Malden (MA). R. Sawaya (Ed.).
66. Pestalozzi B.C., Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000, 18(11):2349-2351.
67. Choong N.W., Dietrich S., Seiwert T.Y., et al. Gefitinib response of erlotinib-refractory lung cancer involving meninges-role of EGFR mutation. Nat Clin Pract Oncol 2006, 3(1):50-57.
68. Jackman D.M., Holmes A.J., Lindeman N., et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006, 24(27):4517-4520.
69. Kanaji N., Bandoh S., Nagamura N., et al. Significance of an epidermal growth factor receptor mutation in cerebrospinal fluid for carcinomatous meningitis. Intern Med 2007, 46(19):1651-1655.
70. Chamberlain M.C., Tsao-Wei D.D., Groshen S. Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer 2006, 106(9):2021-2027.
71. Groves M.D., Glantz M.J., Chamberlain M.C., et al. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol 2008, 10(2):208-215.
72. Wong F.C., Groves M., Hsu S., et al. Safety and radiation dosimetry profiles of intrathecal I-131 sodium iodide (NaI) in patients with leptomeningeal metastasis (LM) [abstract 3107]. ASCO Annual Meeting Proceedings. J Clin Oncol 2005, 23(16s).
73. Kramer K., Humm J.L., Souweidane M.M., et al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol 2007, 25(34):5465-5470.
74. Rubenstein J.L., Combs D., Rosenberg J., et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003, 101(2):466-468.
75. Rubenstein J.L., Fridlyand J., Abrey L., et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007, 25(11):1350-1356.
76. Jaime-Perez J.C., Rodriguez-Romo L.N., Gonzalez-Llano O., et al. Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy. Br J Haematol 2009, 144(5):794-795.
77. Stemmler H.J., Schmitt M., Willems A., et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007, 18(1):23-28.
78. Laufman L.R., Forsthoefel K.F. Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer 2001, 2(3):235.
79. Platini C., Long J., Walter S. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 2006, 7(9):778-780.
80. Stemmler H.J., Schmitt M., Harbeck N., et al. Application of intrathecal trastuzumab (Herceptin™) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 2006, 15(5):1373-1377.
81. Allison D.L., Glantz M., Werner T.L., et al. Intra-CSF trastuzumab in patients with neoplastic meningitis from breast cancer or primary brain tumors[abstract 2066]. ASCO Annual Meeting Proceedings. J Clin Oncol 2009, 27(15s).
82. Hill F.G., Richards S., Gibson B., et al. Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172). Br J Haematol 2004, 124(1):33-46.
83. Hill Q.A., Owen R.G. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 2006, 20(6):319-332.
84. Heideman R.L., Cole D.E., Balis F., et al. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 1989, 49(3):736-741.
85. Vassal G., Gouyette A., Hartmann O., et al. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 1989, 24(6):386-390.
86. Ostermann S., Csajka C., Buclin T., et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 2004, 10(11):3728-3736.
87. Grygiel J.J., Balis F.M., Collins J.M., et al. Pharmacokinetics of tiazofurin in the plasma and cerebrospinal fluid of rhesus monkeys. Cancer Res 1985, 45(5):2037-2039.
88. Zimm S., Ettinger L.J., Holcenberg J.S., et al. Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. Cancer Res 1985, 45(4):1869-1873.
89. Kerr I.G., Zimm S., Collins J.M., et al. Effect of intravenous dose and schedule on cerebrospinal fluid pharmacokinetics of 5-fluorouracil in the monkey. Cancer Res 1984, 44(11):4929-4932.
90. Heideman R.L., Balis F.M., McCully C., et al. Preclinical pharmacology of arabinosyl-5-azacytidine in nonhuman primates. Cancer Res 1988, 48(15):4294-4298.
91. Balis F.M., Poplack D.G. Central nervous system pharmacology of antileukemic drugs. Am J Pediatr Hematol Oncol 1989, 11(1):74-86.
92. Slevin M.L., Piall E.M., Aherne G.W., et al. Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol 1983, 1(9):546-551.
93. Baker S.D., Heideman R.L., Crom W.R., et al. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Cancer Chemother Pharmacol 1996, 37(3):195-202.
94. Beckloff G.L., Lerner H.J., Frost D., et al. Hydroxyurea (NSC-32065) in biologic fluids: dose-concentration relationship. Cancer Chemother Rep 1965, 48:57-58.
95. Yule S.M., Price L., Pearson A.D., et al. Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children. Clin Cancer Res 1997, 3(11):1985-1992.
96. Blaney S.M., Balis F.M., Berg S., et al. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol 2005, 23(7):1555-1563.
97. Blaney S.M., Boyett J., Friedman H., et al. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a Pediatric Brain Tumor Consortium study (PBTC-001). J Clin Oncol 2005, 23(3):525-531.
98. Gururangan S., Petros W.P., Poussaint T.Y., et al. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). Clin Cancer Res 2006, 12(5):1540-1546.
99. Quinn J.A., Glantz M., Petros W., et al. Intrathecal spartaject busulfan phase I trial for patients with neoplastic meningitis. Neuro Oncol 2001, 3(4):364.
100. Nakagawa H., Miyahara E., Suzuki T., et al. Continuous intrathecal administration of 5-fluoro-2′-deoxyuridine for the treatment of neoplastic meningitis. Neurosurgery 2005, 57(2):266-280.